VLCD’s – Translating research findings to sustainable real-world outcomes

‘VLCD’s – Translating research to sustainable real-world outcomes’

The total-care approach for type 2 diabetes has evolved over past few years, with numerous therapeutic options available to improve glycaemic management and impact positively on meaningful outcomes such as cardiovascular events. Among these, therapeutic, medically supervised Very Low-Calorie Diets (VLCDs) and GLP-1 receptor agonists have gained attention due to their potential to significantly impact weight management, enhance insulin sensitivity and reduce cardiovascular risks. However, these interventions differ in their mechanisms of action, efficacy, and long-term sustainability.

A VLCD typically involves a caloric intake of ≤800 kcal per day and is designed to induce significant weight loss. Studies have shown that VLCDs can lead to rapid and substantial reductions in HbA1c, with some individuals even achieving partial or complete remission of their diabetes. The weight loss associated with VLCDs contributes to improved metabolic outcomes by reducing visceral fat, enhancing insulin receptor function and lowering inflammation, all of which are meaningful for individuals with type 2 diabetes. However, the restrictive nature of VLCDs may limit long-term adherence, and the rapid weight loss can be accompanied by loss of muscle mass, making sustained benefits challenging without proper nutritional guidance and monitoring.

In contrast, GLP-1 receptor agonists, such as liraglutide and semaglutide, function by mimicking the glucagon-like peptide-1 hormone, which increases insulin secretion in response to meals, inhibits glucagon release, and promotes satiety. These drugs are particularly effective in reducing blood glucose as well as promoting weight loss. GLP-1 receptor agonists have been shown to provide gradual, sustainable weight loss and improved glycaemic outcomes without the restrictive nature of a VLCD. Furthermore, their impact on appetite regulation offers an advantage over VLCDs, thus providing a more manageable long-term solution.

Ultimately, while both VLCDs and GLP-1 treatments offer significant benefits in diabetes management, their application depends on client-specific factors, including preferences, health status and long-term adherence. This is important given that global diabetes consensus guidelines advocate for an individualized approach to diabetes care.